Skip to content
Distinct breast cancer phenotypes in BRCA 1/2 carriers based on ER status.
Rosenberg S, Devir M, Kaduri L, Grinshpun A, Miner V, Hamburger T, Granit A, Nissan A, Maymon O, Peretz T.
Breast Cancer Res Treat. 2023 Feb 2. doi: 10.1007/s10549-022-06851-6. Epub ahead of print.
Mutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC.
Wahner A.
OncLive. 2023 Feb 1.
The Role of PARP Inhibitors in Non-BRCA Mutated Breast Cancer.
Ballinger TJ.
Medscape Oncology. Decision Point. 2023 Jan 13.
Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
Lee SS, Karpel HC, Oh C, Smith J, Pothuri B.
Gynecol Oncol. 2023 Jan 30;170:234-240. doi: 10.1016/j.ygyno.2022.12.012. Epub ahead of print.
Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis.
Yang Y, Yang X, Li H, Tong X, Zhu X.
J Obstet Gynaecol. 2023 Dec;43(1):2151883. doi: 10.1080/01443615.2022.2151883. Epub 2022 Dec 9.
Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.
Li Y.
J Obstet Gynaecol. 2023 Dec;43(1):2171282. doi: 10.1080/01443615.2023.2171282.
A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer.
Yildirim HC, Ismayilov R, Akyildiz A, Guven DC, Abdurrahimli N, Dizdar O, Yalcin S.
Anticancer Drugs. 2022 Dec 19. doi: 10.1097/CAD.0000000000001486. Epub ahead of print.
Post navigation